Medibact GuidesShop at Medibact

Stacking Module

LL-37 Stacking Module

LL-37 is an antimicrobial peptide, which gives it a genuinely different place in the repair group — it is the only compound here whose primary studied activity is against pathogens rather than on host signaling. That also gives it the group's most specific caution: it is a double-edged molecule in its own literature.

LL-37 Guide at MedibactLL-37 calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking LL-37

  • LL-37 is a cathelicidin antimicrobial peptide with both direct antimicrobial and immunomodulatory activity. That dual nature is why it appears in gut and immune stacks rather than purely structural repair ones.
  • Its own literature associates it with inflammatory and autoimmune conditions as well as with host defence — it is implicated in the pathology of some conditions, not only in resolving them. That is an unusual and important caveat.
  • Human data are limited and it is not approved for any use.
  • No controlled trial has studied LL-37 combined with anything.

Combinations in detail

Gut & Immune Trio

LL-37 + BPC-157 + KPV
Why it is proposed
Three different angles on gut and inflammatory contexts: antimicrobial/immunomodulatory activity, barrier repair signaling, and alpha-MSH-fragment anti-inflammatory signaling.
What is reported in practice
Reported as separate vials; oral and localized routes are discussed for KPV and BPC-157 in gut contexts.
Cautions specific to this combination
LL-37's association with inflammatory pathology in some literature sits awkwardly with combining it with two anti-inflammatory compounds — the mechanisms may not pull in the same direction. Gastrointestinal conditions serious enough to prompt this warrant clinical assessment.

Repair & Recovery Stack

LL-37 + BPC-157 + TB-500
Why it is proposed
Adds the canonical repair pairing to LL-37's immunomodulatory activity.
What is reported in practice
Separate vials on separate schedules.
Cautions specific to this combination
Three compounds, no combination data, and scale differences between BPC-157 (micrograms) and TB-500 (milligrams).

Skin & Tissue Support

LL-37 + GHK-Cu
Why it is proposed
Antimicrobial and immunomodulatory activity alongside copper-driven matrix remodeling, in skin contexts.
What is reported in practice
Separate compounds; GHK-Cu's strongest evidence is topical.
Cautions specific to this combination
LL-37 is implicated in rosacea and some inflammatory skin conditions in its own literature — using it for a skin objective is not straightforwardly beneficial.

What to avoid, and why

  • Treating LL-37 as unambiguously anti-inflammatory; its literature implicates it in inflammatory pathology as well as host defence.
  • Using it for a skin objective without knowing its association with inflammatory skin conditions.
  • Assuming antimicrobial activity is a general benefit — it acts on host immune signaling too.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.